Rheumatologic Disease — Ocular Manifestations

Overview

The eye is disproportionately vulnerable to systemic rheumatologic disease. The cornea, sclera, uvea, and lacrimal gland are all richly vascularized, immunologically active tissues that share the same circulating autoantibodies, immune complexes, and inflammatory cytokines driving joint and connective-tissue disease elsewhere in the body — so when a systemic autoimmune process flares, the eye frequently flares with it. In some diseases the ocular involvement is a late complication of established disease; in others, particularly juvenile idiopathic arthritis, it is a silent process that runs almost entirely independent of joint symptoms and is only caught through scheduled screening.

This is also one of the clearest examples in ophthalmology of the eye exam as a window into undiagnosed systemic disease. A patient can present to an ophthalmologist with red eye, scleritis, or a corneal melt with no prior rheumatologic diagnosis at all, and the pattern of ocular findings — their laterality, their association with pain, the tissue involved — can be specific enough to point directly at a systemic workup that a general physician might not otherwise have ordered. Necrotizing scleritis and peripheral ulcerative keratitis in particular are not just local eye problems; they are markers of active systemic vasculitis that carry real morbidity and mortality risk if the underlying disease goes untreated.

The clusters below span a spectrum from the very common and comparatively benign (dry eye in rheumatoid arthritis) to sight- and life-threatening emergencies (necrotizing scleritis, corneal perforation) to a pediatric disease that is dangerous specifically because it doesn't hurt (chronic anterior uveitis in juvenile idiopathic arthritis). Recognizing which is which — and knowing when topical treatment is adequate versus when the finding demands an urgent rheumatology referral and systemic immunosuppression — is the core clinical skill this page is built around.

Clinical Features

Rheumatoid Arthritis

The single most common ocular manifestation of rheumatoid arthritis (RA) is not scleritis — it's keratoconjunctivitis sicca, or dry eye, affecting up to a third of RA patients. Chronic autoimmune inflammation infiltrates and damages the lacrimal gland, reducing aqueous tear production and producing the classic gritty, burning, foreign-body sensation that so many RA patients report long before any dramatic scleral finding ever develops.

Scleral disease in RA spans a wide severity range. At the mild-and-common end, episcleritis and diffuse or nodular scleritis cause a painful red eye. At the far, much rarer end sits scleromalacia perforans — a necrotizing form of scleritis seen in longstanding RA that is deceptively quiet: it is classically painless and produces a blue-gray discoloration from marked scleral thinning, with little of the redness or inflammatory injection that pain would otherwise announce, even as it progresses toward perforation. That mismatch between how little it hurts and how much tissue destruction is actually occurring is exactly what makes it dangerous — patients and clinicians alike can under-triage it.

Necrotizing scleritis (with inflammation, unlike scleromalacia perforans) is the ocular signal of active RA-associated systemic vasculitis. It carries real risk of scleral perforation and, because it reflects a systemic vasculitic process rather than a purely local one, carries mortality risk if the underlying vasculitis is left untreated.

Peripheral ulcerative keratitis (PUK) — sometimes called "corneal melt syndrome" — is the corneal counterpart. Immune complex deposition and collagenase-mediated stromal destruction near the limbus produce progressive, crescentic thinning of the peripheral cornea that can rapidly progress to perforation. Like necrotizing scleritis, PUK in an RA patient is not a local corneal problem to be managed with drops alone — it signals active systemic vasculitis and is treated as such.

Sjögren Syndrome

Sjögren syndrome is an autoimmune exocrinopathy defined serologically by anti-Ro/SSA and anti-La/SSB antibodies. Lymphocytic infiltration of the lacrimal and salivary glands produces the syndrome's hallmark combination: keratoconjunctivitis sicca (dry eye) paired with xerostomia (dry mouth). It can occur as a primary disease or secondary to RA or other connective-tissue disease, and its dry-eye mechanism is the same lacrimal-gland autoimmune process described above for RA — the two frequently coexist.

Seronegative Spondyloarthropathies & HLA-B27

HLA-B27 is the allele most strongly linked to this entire disease group — ankylosing spondylitis, reactive arthritis, psoriatic arthritis, and inflammatory-bowel-disease-associated arthritis. Among these, ankylosing spondylitis is specifically the most common cause of HLA-B27-associated anterior uveitis, which classically presents as a recurrent, unilateral (alternating sides between episodes), acutely painful red eye with photophobia.

Reactive arthritis is remembered by its classic triad — urethritis, conjunctivitis, and an asymmetric oligoarthritis — typically triggered by a preceding genitourinary (e.g., Chlamydia) or gastrointestinal infection.

Psoriatic arthritis can likewise be associated with uveitis and is classified using the CASPAR criteria (see Diagnosis below), incorporating the cutaneous and articular features of psoriasis alongside the arthritis itself.

Juvenile Idiopathic Arthritis

Ocular disease in juvenile idiopathic arthritis (JIA) is the pediatric rheumatology story that most changes clinical practice: unlike the acute, painful HLA-B27 uveitis above, JIA-associated chronic anterior uveitis is typically asymptomatic — no red eye, no pain — which is precisely why it is dangerous. It is found by screening slit-lamp exams, not by patients or parents noticing symptoms, and can cause silent, cumulative damage (synechiae, cataract, band keratopathy, glaucoma) if it isn't caught early.

The risk is not evenly distributed across JIA subtypes. Oligoarticular JIA, particularly in young, ANA-positive girls, carries the highest risk of this asymptomatic uveitis among all JIA subtypes — which is why regular ophthalmologic screening intervals (rather than symptom-triggered visits) are the standard of care for this population.

Sarcoidosis, Lupus & Other Connective Tissue Disease

Sarcoidosis is defined histopathologically by noncaseating granulomas — collections of epithelioid histiocytes and multinucleated giant cells — and can affect the lungs, lymph nodes, skin, and eyes. Ocular sarcoidosis most commonly produces a granulomatous uveitis, with mutton-fat keratic precipitates on the corneal endothelium, iris nodules at the pupil margin (Koeppe) or within the iris stroma (Busacca), and posterior synechiae. Posterior segment involvement adds vitritis and a distinctive periphlebitis described as "candle-wax drippings" along the retinal veins.

Systemic lupus erythematosus (SLE) is classified under the 2019 EULAR/ACR criteria, which require a positive ANA as an entry criterion before a weighted scoring system across clinical and immunologic domains is applied.

Relapsing polychondritis, a rarer entity, causes recurrent inflammation and destruction of cartilage — classically the ears, nose, and tracheobronchial tree — and frequently presents with accompanying ocular inflammation, including scleritis.

Diagnosis

Several of these diseases have formal classification criteria worth knowing not just as trivia but because they reflect what actually drives the diagnostic workup:

• Rheumatoid arthritis — anti-cyclic citrullinated peptide (anti-CCP) antibody is more specific than rheumatoid factor and is incorporated into the 2010 ACR/EULAR classification criteria. It can also appear before clinical disease onset, making it useful for early or borderline presentations.
• Ankylosing spondylitis — the modified New York criteria require radiographic sacroiliitis plus at least one clinical criterion: limited lumbar spine motion, low back pain, or reduced chest expansion.
• Psoriatic arthritis — the CASPAR criteria are a point-based system incorporating skin psoriasis, nail dystrophy, dactylitis, a negative rheumatoid factor, and juxta-articular new bone formation.
• Systemic lupus erythematosus — the 2019 EULAR/ACR criteria require a positive ANA as an entry criterion, then a weighted score across additional clinical and immunologic domains.

Beyond formal criteria, the serologic picture matters directly for the ophthalmic exam: anti-Ro/SSA and anti-La/SSB point toward Sjögren syndrome in a patient with sicca symptoms, and HLA-B27 typing supports (though does not by itself confirm) a spondyloarthropathy in a patient with recurrent, alternating, acutely painful anterior uveitis.

Management

The single most important management principle on this page is that RA-associated necrotizing scleritis and peripheral ulcerative keratitis are systemic vasculitis emergencies, not local eye problems. Both require systemic immunosuppression — oral corticosteroids paired with a steroid-sparing agent such as methotrexate or cyclophosphamide — to control the underlying vasculitic process and prevent perforation. Topical steroids or NSAIDs alone, or simple observation, are inadequate: they may quiet the eye's appearance without addressing the systemic disease actually destroying the tissue.

Milder RA-associated dry eye, by contrast, is managed the way sicca disease usually is — lubrication, anti-inflammatory drops, and punctal occlusion as needed — without systemic escalation, underscoring that not every RA ocular finding carries the same urgency.

For JIA-associated chronic anterior uveitis that remains active despite methotrexate, the evidence-based next step is escalation to adalimumab, a TNF-alpha inhibitor. This is grounded in randomized trial evidence — the SYCAMORE trial — which showed that adding adalimumab reduced treatment failure and flares compared with methotrexate alone, making it the standard first-line biologic add-on for refractory JIA uveitis.

Related Topics

Continue exploring Systemic Disease & the Eye: